Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-28T19:35:53.367Z Has data issue: false hasContentIssue false

Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI)

Published online by Cambridge University Press:  11 October 2011

Luca Arduini
Affiliation:
Dipartimento di Medicina Sperimentale, Università de L'Aquila, L'Aqulla
Stefano De Cataldo
Affiliation:
Dipartimento di Salute Mentale ASL 4, L'Aquila
Paolo Stratta
Affiliation:
Dipartimento di Salute Mentale ASL 4, L'Aquila

Summary

Objective – Aim of the study was to investigate the psychometric properties of the Italian version of the Drug Attitude Inventory (DAI) by exploring its construct validity. Setting – 90 voluntary admitted patients with DSM III-R Schizophrenic (n.72) and Schizoaffective (n.18) disorders, age range between 18 and 50 years, treated with typical antipsychotics, able to participate in the study, were selected. Design – Exploratory factor analyses with alpha factoring and maximum–likelihood methods with Varimax Rotation were used to analyse DAI scores. Results – Extraction methods found 7 factors which explained 62.5% of the total variance. The first 2 factors could be labelled as “subjective response to treatment” construct and factors 3 to 7 as “attitude to medication” contruct. Conclusion – Although preliminarily, the Italian version of the DAI seems to maintain the original psychometric properties and it can be used easily to get a valid measurement of the patients' attitude to neuroleptic medication.

Riassunto

Scopo – Verificare se la versione italiana della Drug Attitude Inventory mantiene le proprietà psicometriche del questionario originate attraverso una validazione di costrutto. Setting – Lo studio è stato condotto su 90 pazienti con diagnosi di Disturbo Schizofrenico (n=72) e Disturbo Schizoaffettivo (n=18) ammessi al ricovero volontario per un episodio indice di riesacerbazione psicotica, d'età compresa tra i 18 ed i 50 anni, in trattamento con farmaci antipsicotici tipici e cognitivamente in grado di comprendere e rispondere alle domande del questionario. Disegno – Sono state impiegate analisi fattoriali esplorative con i metodi d'estrazione alfa fattoriale e della massima verosimiglianza; successivamente è stato utilizzato il metodo di Rotazione Varimax. Risultati – I metodi d'estrazione utilizzati trovavano 7 fattori che spiegavano il 62.5% della varianza. I primi 2 fattori possono essere identificati nel costrutto di “risposta soggettiva al trattamento” ed i fattori da 3 a 7 nel costrutto di “atteggiamento nei confronti della terapia”. Conclusioni – Benché lo studio sia preliminare, la traduzione italiana dello strumento sembra mantenere le proprietà psicometriche della versione originale e può essere utilizzata nella pratica clinica per una valida misurazione deH'atteggiamento del paziente nei confronti del trattamento con farmaci antipsicotici.

Type
Articles
Copyright
Copyright © Cambridge University Press 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

BIBLIOGRAFIA

American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders (3rd. ed. rev.). American Psychiatric Association: Washington DC.Google Scholar
Awad, A.G.(1993) Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 3, 609616.CrossRefGoogle Scholar
Awad, A.G., Voruganti, L.N.P., Heslegrave, R.J. & Hogan, T.P. (1996). Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. International Clinical Psychopharmacology 11, 5559.CrossRefGoogle ScholarPubMed
Bebbington, P.E. (1995). The content and context of compliance. International Clinical Psychopharmacology 9, Suppl. No. 5, 4150.CrossRefGoogle ScholarPubMed
Bonsack, C.H., Conus, P.H., Philippoz, R., Bovet, J., Spagnoli, J. & Dufour, H. (1998). La perception subjective de I'effect des neuroleptic chez des patients schizophrenes ambulatoires: un etude transversale. Encephale 24, 315323.Google Scholar
Corrigan, P.W., Liberman, R.P. & Engel, J.D. (1990). From noncompliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 41,12031211.Google ScholarPubMed
Day, J.C., Kinderman, P. & Bentall, R. (1998). A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Ada Psychiatrica Scandinavica 97, 9397.CrossRefGoogle ScholarPubMed
Di Mascio, A. (1970). Behavioral toxicity. In Clinical Handbook of Psychopharmacology (ed. Mascio, A. Di and Shader, R.I.), pp. 185193. Science House: New York.Google Scholar
Healey, A., Knapp, M., Astin, J., Beecham, J., Kemp, R., Kirov, J. & David, A. (1998). Cost-effectiveness evaluation of compliance therapy for people with psychosis. British Journal of Psychiatry 172, 420424.CrossRefGoogle ScholarPubMed
Hogan, T.P., Awad, A.G. & Eastwood, R. (1983). A self-report scale predicitive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 13, 177183.CrossRefGoogle Scholar
Hogan, T.P., Awad, A.G. & Eastwood, R. (1985). Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Canadian Journal of Psychiatry 30, 246248.CrossRefGoogle ScholarPubMed
Hogarty, G.E., Schooler, N.R., Ulrich, R.F., Mussare, F., Ferro, P. & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36, 12831294.CrossRefGoogle Scholar
Hoge, S.K., Appelbaum, P.S., Lawlor, T., Beck, J.C., Litman, R., Greer, A., Gutheil, T.G. & Kaplan, E. (1990). A prospective, multicenter study of patients' refusal of antipsychotic medication. Archives of General Psychiatry 47, 949956.CrossRefGoogle ScholarPubMed
Kampman, O. & Lehtinen, K. (1999). Compliance in psychoses. Ada Psychiatrica Scandinavica 100, 167175.CrossRefGoogle ScholarPubMed
Kemp, R. & David, A. (1995). Insight and adherence to treatment in psychotic disorders. British Journal Hospital Medicine 54,222227.Google ScholarPubMed
Kemp, R. & David, A. (1996). Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry 169, 444450.CrossRefGoogle ScholarPubMed
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. & David, A. (1996) Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal 312, 345349.CrossRefGoogle ScholarPubMed
Kemp, R., Kirov, G., Everitt, B., Hayward, P. & David, A. (1998). Randomised controlled trial of compliance therapy. British Journal of Psychiatry 172, 413419.CrossRefGoogle ScholarPubMed
Lipowski, Z.J. (1977). The importance of body experience for psychiatry. Comprehensive Psychiatry 18, 473479.CrossRefGoogle ScholarPubMed
May, P.R.A., Van Putten, T. & Yale, C. (1976). Predicting individual responses to drug treatment in schizophrenia: a test dose model. Journal of Nervous and Mental Disease 162, 177183.CrossRefGoogle ScholarPubMed
May, P.R.A., Van Putten, T., Jenden, D.J, Yale, C, Dixon, W.J. & Goldstein, M.J. (1981). Prognosis in schizophrenia: individual differences in psychological response to a tes dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Comprehensive Psychiatry 22, 147152.CrossRefGoogle Scholar
Naber, D. (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 10, Suppl. No. 3, 133138.Google ScholarPubMed
Norusis, M.J. (1992). SPSS for Windows: Base System User's Guide. Release 5.0. SPSS Inc.: Chicago.Google Scholar
Rossi, A., Arduini, L., Stratta, P. & Pallanti, S. (2000). Subjective experience and subjective response to neuroleptic in schizophrenia. Comprehensive Psychiatry, 6, 446–9.CrossRefGoogle Scholar
Simonsen, E. & Mortensen, E.L. (1990). Difficulties in translation of personality scales. Journal of Personality Disorders 4, 290296.CrossRefGoogle Scholar
Singh, M.M. (1976). Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 37, 191196.Google ScholarPubMed
Van Putten, T. & May, P.R.A. (1978). Subjective response as a predictor of outocome in pharmacotherapy. Archives of General Psychiatry 35, 477480.CrossRefGoogle Scholar
Van Putten, T., May, P.R.A., Jenden, D.J., Cho, A.K. & Yale, C. (1980a). Plasma and saliva levels of chlorpromazine and subjective response. American Journal of Psychiatry 137, 12411242.Google ScholarPubMed
Van Putten, T., May, P.R.A. & Marder, S.R. (1980b). Subjective responses to thiothixene and chlorpromazine. Psychopharmacology Bulletin 16, 3638.Google Scholar
Van Putten, T., May, P.R.A., Marder, S.R. & Wittam, L. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry 38, 187190.CrossRefGoogle ScholarPubMed
Weiden, P.J., Mann, J.J., Haas, G., Mattson, M. & Frances, A. (1987). Clinical Non recognition of neuroleptic-Induced Movement Disorder: a cautionary study. American Journal of Psychiatry 144, 11481153.Google ScholarPubMed
Weiden, P., Rapkin, B., Mott, T., Zygmunt, A., Goldman, D., Horvitz-Lennon, M. & Frances, A. (1994). Rating of Medication Influences Scale (ROMI) in schizophrenia. Schizophrenia Bulletin 20, 297307.CrossRefGoogle ScholarPubMed